Medscape is available in 5 Language Editions – Choose your Edition here.


Pediatric Hepatoblastoma

  • Author: Jennifer Reikes Willert, MD; Chief Editor: Max J Coppes, MD, PhD, MBA  more...
Updated: Nov 17, 2014

Practice Essentials

Hepatoblastoma (see the image below) is the most common form of liver cancer in children, although it is a comparatively uncommon pediatric solid tumor. The disease usually affects children younger than 3 years.

Clear cell hepatoblastoma. Hematoxylin and eosin s Clear cell hepatoblastoma. Hematoxylin and eosin stain. Image courtesy of Denise Malicki, MD.

Essential update: Study suggests fewer chemotherapy courses just as effective for resectability of hepatoblastoma

Standard clinical management of hepatoblastoma in pediatric patients includes a combined total of six courses of preoperative and postoperative chemotherapy. However, in a retrospective study of 20 pediatric patients with grade III and IV surgically unresectable hepatoblastomas, Venkatramani et al found that many cases were resectable after just two cycles of neoadjuvant chemotherapy.[1, 2]

At initial diagnosis, 16 of the 20 tumors (80%) were considered unresectable.[2] After two courses of chemotherapy, seven (35%) were considered unresectable, and after four courses of chemotherapy, four (20%) were considered unresectable. All four of the tumors considered unresectable after four cycles of chemotherapy would have qualified for liver transplantation.

Signs and symptoms

Hepatoblastoma is usually diagnosed as an asymptomatic abdominal mass. Patients may also display the following:

  • Hemihyperplasia: An incidental finding in approximately 10% of patients
  • Isosexual precocity: Penile and testicular enlargement without pubic hair is seen in patients with tumors that secrete the b subunit of human chorionic gonadotropin (b-hCG).
  • Late features of Beckwith-Wiedemann syndrome (BWS): Rare; include midface hypoplasia and slitlike indentations of the earlobe
  • Anorexia: In advanced disease
  • Talipes equinovarus
  • Persistent ductus arteriosus
  • Tetralogy of Fallot
  • Extrahepatic biliary atresia
  • Renal anomalies (dysplastic kidney, horseshoe kidney)
  • Cleft palate
  • Dysplasia of the earlobes
  • Goldenhar syndrome
  • Prader-Willi syndrome
  • Meckel diverticulum
  • Simpson-Golabi-Behmel syndrome
  • Sotto Syndrome
  • Symptoms associated with osteopenia: Severe osteopenia is present in most patients, but, with the exception of pathologic fracture, symptoms are rare
  • Symptoms of acute abdomen: Rare; occur if the tumor ruptures
  • Severe anemia: Occurs occasionally, as a result of tumor rupture and hemorrhage

See Clinical Presentation for more detail.


Lab studies

  • Complete blood count (CBC) with differential: Normochromic normocytic anemia and thrombocytosis may be present
  • Liver enzyme levels: Moderately elevated in 15-30% of patients
  • α-fetoprotein (AFP) - levels in hepatoblastoma are often as high as 100,000-300,000 mcg/mL

Imaging studies

  • Radiography: Reveals mass in the right upper quadrant of the abdomen
  • Ultrasonography: Allows assessment of tumor size and anatomy
  • Computed tomography (CT) scanning: Reveals involvement of nearby structures and whether pulmonary metastases are present
  • Magnetic resonance imaging (MRI): Believed to be superior to CT scanning but does not necessarily add to the anatomic detail seen on CT scans
  • Positron emission tomography (PET) scanning: May have a role in diagnosis and follow-up evaluation
  • Radionuclide bone scanning: To evaluate for bone metastases in symptomatic patients


Surgical resection is the usual manner in which material for pathologic assessment is obtained. Open biopsy is performed when complete surgical resection is not possible. Needle biopsy is not recommended, because hepatoblastomas usually are highly vascular.


  • Stage I: Tumor is completely resectable via wedge resection or lobectomy; tumor has pure fetal histologic (PFH) results; AFP level is within reference range within 4 weeks of surgery
  • Stage IIA: Tumor is completely resectable; tumor has histologic results other than PFH (unfavorable histology [UH])
  • Stage IIB: Tumor is completely resectable; AFP findings are negative at time of diagnosis (ie, no marker to follow)
  • Stage IIC: Tumor is completely resected or is rendered completely resectable by initial radiotherapy or chemotherapy or microscopic residual disease is present; AFP level is elevated 4 weeks after resection
  • Stage III (any of the following): Either the tumor is initially unresectable but is confined to 1 lobe of the liver, gross residual disease is present after surgery, the tumor ruptures or spills preoperatively or intraoperatively, or regional lymph nodes are involved
  • Stage IV: Distant bone or lung metastasis has occurred

See Workup for more detail.



  • Cisplatin is the most active single agent used to treat hepatoblastoma
  • The cisplatin/5-fluorouracil (5-FU)/vincristine (VCR) combination is regarded as standard chemotherapeutic treatment in hepatoblastoma
  • Preoperative chemotherapy can completely eradicate metastatic pulmonary disease and multinodular liver disease
  • Postoperatively, chemotherapy is usually started approximately 4 weeks after surgery to allow liver regeneration


  • Doses used for treatment of hepatoblastoma are usually 1200-2000 centigray (cGy)
  • Radiotherapy may be used when microscopic disease is seen at the resection margins
  • Adjuvant radiotherapy may have a role in the treatment of chemoresistant pulmonary metastases

Resection and transplantation

  • Lobectomy: Initial resection of operable primary tumors by lobectomy is the standard of care in hepatoblastoma
  • Liver transplantation: Has had an increasing role in children with nonresectable tumors or in those who show chemotherapy resistance
  • Thoracotomy and resection of pulmonary metastases: Some patients have long-term, disease-free survival when aggressive attempts are made to surgically eradicate all areas of disease

See Treatment and Medication for more detail.



Hepatoblastoma is the most common liver cancer in children, although it is relatively uncommon compared with other solid tumors in the pediatric age group. Over the past several years, pathologic variations of hepatoblastoma have been identified, and techniques for establishing the diagnosis of childhood hepatic tumors have improved. Surgical techniques and adjuvant chemotherapy have markedly improved the prognosis of children with hepatoblastoma. Complete surgical resection of the tumor at diagnosis, followed by adjuvant chemotherapy, is associated with 100% survival rates, but the outlook remains poor in children with residual disease after initial resection, even if they receive aggressive adjuvant therapy.

Considerable controversy has surrounded the discrepancy between US and international hepatoblastoma therapeutic protocols; surgery and staging are initially advised in the United States, whereas adjuvant therapy is strongly considered internationally. Significant data now support a role for preoperative neoadjuvant chemotherapy if the tumor is inoperable or if the tumor is unlikely to achieve gross total resection at initial diagnosis.[3] Early involvement of hepatologists and liver transplant teams is recommended if the tumor may not be completely resectable even with preoperative adjuvant chemotherapy. Liver transplantation is playing an increasing role in cases in which the tumor is deemed nonresectable after chemotherapy is administered or in "rescue" transplantation when initial surgery and chemotherapy are not successful.[4, 5]

Finally, reports state that aggressive surgical intervention may be warranted for isolated pulmonary metastases.[3, 6]



Hepatoblastomas originate from immature liver precursor cells and present morphologic features that mimic normal liver development. Hepatoblastomas are usually unifocal and affect the right lobe of the liver more often than the left lobe. Microvascular spread can extend beyond the apparently encapsulated tumor.

Grossly, the tumor is a tan bulging mass with a pseudocapsule. Cirrhosis is not associated with this tumor. Metastases affect the lungs and the porta hepatis; bone metastases are very rare. CNS involvement has been reported at diagnosis and during relapse. The identification of distinct subtypes and further molecular biological information derived regarding liver ontogenesis and growth regulation of hepatic tumors has recently helped pave the way for a more comprehensive classification system for this disease.

Loss of heterozygosity (LOH) of chromosome arm 11p markers occurs commonly in hepatoblastoma identified in association with Beckwith-Wiedemann syndrome (BWS) and hemihypertrophy. Isochromosome 8q is seen in mixed hepatoblastomas, and trisomy 20 is seen in pure epithelial hepatoblastomas (see Histologic Findings).

Patients with familial adenomatous polyposis (FAP), a syndrome of early-onset colonic polyps and adenocarcinoma, frequently develop hepatoblastomas. Germline mutations in the APC tumor suppressor gene occur in patients with FAP, and mutations in the APC tumor suppressor gene are frequently detected in the colonic polyps and adenocarcinomas associated with FAP. One study estimated that 1 in 20 hepatoblastomas is probably associated with FAP.[7] Interestingly, APC mutations, although common in patients with hepatoblastoma and FAP, are rare in patients with sporadic hepatoblastomas. Recently, Sanders and Furman reported 2 brothers with hepatoblastoma who had a significant family history of early onset colon cancer.[8] Testing of the younger brother revealed a deletion in exon 15 of the APC gene consistent with a diagnosis of FAP.

In a study of 29 tumors from children with sporadic hepatoblastoma, no germline APC mutations were found.[9] These authors conclude that routine APC screening does not need to be performed in these children without a family history of colorectal cancer or FAP.

Loss of function mutations in APC lead to intracellular accumulation of the protooncogene b-catenin, an effector of Wnt signal transduction. b-catenin mutations have been shown to be common in sporadic hepatoblastomas, occurring in as many as 67% of patients. Furthermore, a study in a mouse model of hepatoblastomas induced by toxin exposure detected mutations of the b-catenin protooncogene in 100% of the tumors analyzed (27 of 27).[10] This finding suggests that alterations in the Wnt signaling pathway likely contribute to the neoplastic process in this particular tumor.

Recent studies on other components of the Wnt signaling pathway have also demonstrated a likely role for constitutive activation of this pathway in the etiology of hepatoblastoma.[11, 12] Overexpression of human Dickkopf-1, a known antagonist of the Wnt pathway, has been found in hepatoblastoma. The authors postulate that this may be a direct negative feedback mechanism resulting from increased β-catenin commonly found in this tumor.[13]

A mutation in the axin gene, also a known antagonist of β-catenin accumulation, has been found in hepatoblastoma and may contribute to the etiology of the smaller percentage of hepatoblastomas in which β-catenin mutations have not been identified, thus implicating the constitutive activation of the Wnt pathway in a significant fraction of hepatoblastomas.[14, 15] Kuroda et al demonstrated a potential role for transcriptional targeting of tumors with strong β-catenin/T-cell factor activity with oncolytic herpes simplex virus vector.[16] The hedgehog (Hh) pathway has also been evaluated and has been found to be a potential therapeutic target for hepatoblastomas in which the Hh pathway is overexpressed or reactivated at an inappropriate time.[17]

Blocking the Hh pathway with the antagonist cyclonamine has shown a strong inhibitory effect on hepatoblastoma cell line proliferation. A high frequency of glioma-associated oncogene homolog 1 (GLI1) and patched homolog 1 (PTCH1) overexpression and Hh-interacting protein (HHIP) promoter methylation is noted in early childhood hepatoblastoma, which also supports a key role for Hh signalling activation in malignant transformation of embryonal liver cells.[18]

Wnt pathway activation appears to be more prevalent in embryonal and mixed subtypes of hepatoblastoma, whereas notch pathway activation is more prevalent with the more differentiated pure fetal hepatoblastoma tumors.[19] The relative activation of Hh, Wnt, and notched signaling pathways appears to be useful in stratification of different subtypes.

Increasing evidence suggests that hepatoblastoma is derived from a pluripotent stem cell.[20] This further supports the hypothesis that this tumor arises from a developmental error during hepatogenesis and supports the hypothesis that research particularly focused on these developmental processes governing liver maturation and growth may ultimately lead to more effective targeted therapy for this disease.



United States

Hepatoblastoma accounts for 79% of all liver tumors in children and almost two thirds of primary malignant liver tumors in the pediatric age group. Approximately 100 cases of hepatoblastoma are reported per year. The annual incidence of hepatoblastoma in infants younger than 1 year is 11.2 cases per million; in 1990-1995, the annual incidence in children overall was 1.5 cases per million, which is almost double the incidence from 1975-1979.

A significantly higher rate of hepatoblastomas is observed among low birth weight (LBW) and very low birth weight (VLBW) infants born prematurely.[21]

A Children’s Oncology Group (COG) protocol (AEP104C1) is currently investigating exogenous and endogenous causes for the increase in incidence and potential cause of premature births. The study is also exploring potential effectors independent of prematurity and LBW or VLBW. All children with hepatoblastoma diagnosed before age 6 years from 2000-2005 are eligible for retrospective analysis, and prospective analysis will be performed for children diagnosed between June 2005 and December 31, 2008. This is the largest, most comprehensive case-control study of hepatoblastoma performed thus far.


In Japan, efforts to improve vaccination rates have led to decreases in hepatocellular carcinoma (HCC) and, to a lesser degree, in hepatoblastoma. Carcinogen exposure in some developing countries is linked to hepatoblastoma and HCC.



A large multicenter COG study included 182 children with hepatoblastoma diagnosed between August 1989 and December 1992.[22] Of these, 9 had stage I disease with favorable histology (FH), 43 had stage I with unfavorable histology (UH), 7 had stage II, 83 had stage III, and 40 had stage IV disease (see Staging).

All 9 patients with stage I and FH received treatment with low-dose doxorubicin and were alive and free of disease. Overall survival rates for all stages 5 years after treatment were 57-69%. The 5-year event-free survival (EFS) rates were 91% for patients with stage I with UH, 100% for stage II, 64% for stage III, and 25% for stage IV.

In general, patients who undergo complete resection of the tumor and adjuvant chemotherapy have a survival rate of 100%. Patients with favorable histology and low mitotic rate with complete resection may not require chemotherapy; for this reason, US protocols have advocated for formal staging and pathologic diagnosis prior to administering any adjuvant chemotherapy.

More recently, data from the International Childhood Liver Tumour Strategy Group (SIOPEL), which used preoperative adjuvant chemotherapy, demonstrated overall survival rates as high as 89% and event-free survival rates as high as 80%.[23] Australian investigators demonstrated that patients treated between 1984 and 2004 also had excellent outcomes, provided surgical margins were clear.[3] No correlation between α-fetoprotein (AFP) levels and outcome was reported in the study.

Other morbidity can result from precancerous medical conditions, operative complications, or toxic effects of chemotherapy. Short- and long-term sequelae and toxic effects of surgical management and chemotherapy are discussed below (see Surgical Care and Medical Care).


White children are affected almost 5 times more frequently than black children. Black patients tend to have worse outcomes.


Males are typically affected more frequently than females; the male-to-female ratio is 1.7:1. Male-to-female ratios are somewhat higher in Europe (1.6-3.3:1) and Taiwan (2.9:1).


Hepatoblastoma usually affects children younger than 3 years, and the median age at diagnosis is 1 year. Hepatoblastoma is very rarely diagnosed in adolescence and is exceedingly rare in adults. Occasionally, nests of hepatoblastoma cells are found in hepatocellular carcinoma lesions; this is more common in adults than in children. Older children and adults tend to have a worse prognosis.

Contributor Information and Disclosures

Jennifer Reikes Willert, MD Associate Clinical Professor, Department of Pediatrics, Division of Pediatric Hematology/Oncology, Section of Stem Cell Transplantation, Stanford University Medical Center, Lucile Packard Children's Hospital

Jennifer Reikes Willert, MD is a member of the following medical societies: American Academy of Pediatrics, American Society of Hematology, American Society for Blood and Marrow Transplantation, Children's Oncology Group, American Society of Pediatric Hematology/Oncology

Disclosure: Nothing to disclose.


Gary Dahl, MD Professor, Department of Pediatrics, Division of Hematology/Oncology, Stanford University School of Medicine

Gary Dahl, MD is a member of the following medical societies: American Society of Hematology, American Society of Pediatric Hematology/Oncology

Disclosure: Nothing to disclose.

Alexandra (Lowry) Abrams, MD Associate Medical Director, George Mark Children’s House

Disclosure: Nothing to disclose.

Arun A Rangaswami, MD Clinical Associate Professor of Pediatrics, Associate Director, Pediatric Hematology-Oncology Fellowship Program, Stanford University School of Medicine

Arun A Rangaswami, MD is a member of the following medical societies: American Academy of Pediatrics, American Medical Association, Children's Oncology Group

Disclosure: Nothing to disclose.

Specialty Editor Board

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Steven K Bergstrom, MD Department of Pediatrics, Division of Hematology-Oncology, Kaiser Permanente Medical Center of Oakland

Steven K Bergstrom, MD is a member of the following medical societies: Alpha Omega Alpha, Children's Oncology Group, American Society of Clinical Oncology, International Society for Experimental Hematology, American Society of Hematology, American Society of Pediatric Hematology/Oncology

Disclosure: Nothing to disclose.

Chief Editor

Max J Coppes, MD, PhD, MBA Executive Vice President, Chief Medical and Academic Officer, Renown Heath

Max J Coppes, MD, PhD, MBA is a member of the following medical societies: American College of Healthcare Executives, American Society of Pediatric Hematology/Oncology, Society for Pediatric Research

Disclosure: Nothing to disclose.

Additional Contributors

Stephan A Grupp, MD, PhD Director, Stem Cell Biology Program, Department of Pediatrics, Division of Oncology, Children's Hospital of Philadelphia; Associate Professor of Pediatrics, University of Pennsylvania School of Medicine

Stephan A Grupp, MD, PhD is a member of the following medical societies: American Association for Cancer Research, Society for Pediatric Research, American Society for Blood and Marrow Transplantation, American Society of Hematology, American Society of Pediatric Hematology/Oncology

Disclosure: Nothing to disclose.


The authors would like to thank all of our patients and families, as well as all of our mentors along this path towards a better outcome for children with hepatoblastoma!

  1. Castellino AM. Children with hepatoblastoma: could less chemo be used?. Medscape Medical News. November 5, 2014. [Full Text].

  2. Venkatramani R, Stein JE, Sapra A, Genyk Y, Jhaveri V, Malogolowkin M, et al. Effect of neoadjuvant chemotherapy on resectability of stage III and IV hepatoblastoma. Br J Surg. 2014 Oct 28. [Medline].

  3. Ang JP, Heath JA, Donath S, Khurana S, Auldist A. Treatment outcomes for hepatoblastoma: an institution's experience over two decades. Pediatr Surg Int. 2007 Feb. 23(2):103-9. [Medline].

  4. Otte JB, Pritchard J, Aronson DC, et al. Liver transplantation for hepatoblastoma: results from the International Society of Pediatric Oncology (SIOP) study SIOPEL-1 and review of the world experience. Pediatr Blood Cancer. 2004 Jan. 42(1):74-83. [Medline].

  5. Otte JB, de Ville de Goyet J, Reding R. Liver transplantation for hepatoblastoma: indications and contraindications in the modern era. Pediatr Transplant. 2005 Oct. 9(5):557-65. [Medline].

  6. Czauderna P, Mackinlay G, Perilongo G, et al. Hepatocellular carcinoma in children: results of the first prospective study of the International Society of Pediatric Oncology group. J Clin Oncol. 2002 Jun 15. 20(12):2798-804. [Medline].

  7. Hirschman BA, Pollock BH, Tomlinson GE. The spectrum of APC mutations in children with hepatoblastoma from familial adenomatous polyposis kindreds. J Pediatr. 2005 Aug. 147(2):263-6. [Medline].

  8. Sanders RP, Furman WL. Familial adenomatous polyposis in two brothers with hepatoblastoma: implications for diagnosis and screening. Pediatr Blood Cancer. 2006 Nov. 47(6):851-4. [Medline].

  9. Harvey J, Clark S, Hyer W, Hadzic N, Tomlinson I, Hinds R. Germline APC mutations are not commonly seen in children with sporadic hepatoblastoma. J Pediatr Gastroenterol Nutr. 2008 Nov. 47(5):675-7. [Medline].

  10. Anna CH, Sills RC, Foley JF, Stockton PS, Ton TV, Devereux TR. Beta-catenin mutations and protein accumulation in all hepatoblastomas examined from B6C3F1 mice treated with anthraquinone or oxazepam. Cancer Res. 2000 Jun 1. 60(11):2864-8. [Medline].

  11. Koch A, Waha A, Hartmann W, et al. Elevated expression of Wnt antagonists is a common event in hepatoblastomas. Clin Cancer Res. 2005 Jun 15. 11(12):4295-304. [Medline].

  12. Tan X, Apte U, Micsenyi A, et al. Epidermal growth factor receptor: a novel target of the Wnt/beta-catenin pathway in liver. Gastroenterology. 2005 Jul. 129(1):285-302. [Medline].

  13. Wirths O, Waha A, Weggen S, et al. Overexpression of human Dickkopf-1, an antagonist of wingless/WNT signaling, in human hepatoblastomas and Wilms' tumors. Lab Invest. 2003 Mar. 83(3):429-34. [Medline].

  14. Miao J, Kusafuka T, Udatsu Y, Okada A. Sequence variants of the Axin gene in hepatoblastoma. Hepatol Res. 2003 Feb. 25(2):174-179. [Medline].

  15. Taniguchi K, Roberts LR, Aderca IN, et al. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Oncogene. 2002 Jul 18. 21(31):4863-71. [Medline].

  16. Kuroda T, Rabkin SD, Martuza RL. Effective treatment of tumors with strong beta-catenin/T-cell factor activity by transcriptionally targeted oncolytic herpes simplex virus vector. Cancer Res. 2006 Oct 15. 66(20):10127-35. [Medline].

  17. Arsic D, Beasley SW, Sullivan MJ. Switched-on Sonic hedgehog: a gene whose activity extends beyond fetal development - to oncogenesis. J Paediatr Child Health. 2007 Jun. 43(6):421-3. [Medline].

  18. Eichenmuller M, Gruner I, Hagl B, et al. Blocking the hedgehog pathway inhibits hepatoblastoma growth. Hepatology. 2009 Feb. 49(2):482-90. [Medline].

  19. Lopez-Terrada D, Gunaratne PH, Adesina AM, et al. Histologic subtypes of hepatoblastoma are characterized by differential canonical Wnt and Notch pathway activation in DLK+ precursors. Hum Pathol. 2009 Jun. 40(6):783-94. [Medline].

  20. Ruck P, Xiao JC. Stem-like cells in hepatoblastoma. Med Pediatr Oncol. 2002 Nov. 39(5):504-7. [Medline].

  21. Tanimura M, Matsui I, Abe J, et al. Increased risk of hepatoblastoma among immature children with a lower birth weight. Cancer Res. 1998 Jul 15. 58(14):3032-5. [Medline].

  22. Ortega JA, Douglass EC, Feusner JH, et al. Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: A report from the Children's Cancer Group and the Pediatric Oncology Group. J Clin Oncol. 2000 Jul. 18(14):2665-75. [Medline].

  23. Aronson DC, Schnater JM, Staalman CR, et al. Predictive value of the pretreatment extent of disease system in hepatoblastoma: results from the International Society of Pediatric Oncology Liver Tumor Study Group SIOPEL-1 study. J Clin Oncol. 2005 Feb 20. 23(6):1245-52. [Medline].

  24. Feusner J, Plaschkes J. Hepatoblastoma and low birth weight: a trend or chance observation?. Med Pediatr Oncol. 2002 Nov. 39(5):508-9. [Medline].

  25. Oue T, Kubota A, Okuyama H, et al. Hepatoblastoma in children of extremely low birth weight: a report from a single perinatal center. J Pediatr Surg. 2003 Jan. 38(1):134-7; discussion 134-7. [Medline].

  26. Ucar C, Caliskan U, Toy H. Hepatoblastoma in a child with neurofibromatosis type I. Pediatr Blood Cancer. 2005 Nov 10. [Medline].

  27. Toxicology and Carcinogenesis Studies of Bromochloroacetic Acid (CAS No. 5589-96-8) in F344/N Rats and B6C3F1 Mice (Drinking Water Studies). Natl Toxicol Program Tech Rep Ser. 2009 Feb. 1-270. [Medline].

  28. Fuchs J, Rydzynski J, Von Schweinitz D, et al. Pretreatment prognostic factors and treatment results in children with hepatoblastoma: a report from the German Cooperative Pediatric Liver Tumor Study HB 94. Cancer. 2002 Jul 1. 95(1):172-82. [Medline].

  29. Figarola MS, McQuiston SA, Wilson F, Powell R. Recurrent hepatoblastoma with localization by PET-CT. Pediatr Radiol. 2005 Dec. 35(12):1254-8. [Medline].

  30. Rowland JM. Hepatoblastoma: assessment of criteria for histologic classification. Med Pediatr Oncol. 2002 Nov. 39(5):478-83. [Medline].

  31. von Schweinitz D, Hecker H, Schmidt-von-Arndt G, Harms D. Prognostic factors and staging systems in childhood hepatoblastoma. Int J Cancer. 1997 Dec 19. 74(6):593-9. [Medline].

  32. Douglass EC, Reynolds M, Finegold M, Cantor AB, Glicksman A. Cisplatin, vincristine, and fluorouracil therapy for hepatoblastoma: a Pediatric Oncology Group study. J Clin Oncol. 1993 Jan. 11(1):96-9. [Medline].

  33. Casanova M, Massimino M, Ferrari A, et al. Etoposide, cisplatin, epirubicin chemotherapy in the treatment of pediatric liver tumors. Pediatr Hematol Oncol. 2005 Apr-May. 22(3):189-98. [Medline].

  34. Perilongo G, Maibach R, Shafford E, et al. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med. 2009 Oct 22. 361(17):1662-70. [Medline].

  35. McCrudden KW, Hopkins B, Frischer J, et al. Anti-VEGF antibody in experimental hepatoblastoma: suppression of tumor growth and altered angiogenesis. J Pediatr Surg. 2003 Mar. 38(3):308-14; discussion 308-14. [Medline].

  36. Warmann S, Gohring G, Teichmann B, Geerlings H, Fuchs J. MDR1 modulators improve the chemotherapy response of human hepatoblastoma to doxorubicin in vitro. J Pediatr Surg. 2002 Nov. 37(11):1579-84. [Medline].

  37. Warmann S, Hunger M, Teichmann B, Flemming P, Gratz KF, Fuchs J. The role of the MDR1 gene in the development of multidrug resistance in human hepatoblastoma: clinical course and in vivo model. Cancer. 2002 Oct 15. 95(8):1795-801. [Medline].

  38. Rana AN, Qidwai A, Pritchard J, Ashraf MS. Successful treatment of multifocal unresectable hepatoblastoma with chemotherapy only. Pediatr Hematol Oncol. 2006 Mar. 23(2):153-8. [Medline].

  39. Widemann BC, Goodspeed W, Goodwin A, Fojo T, Balis FM, Fox E. Phase I trial and pharmacokinetic study of ixabepilone administered daily for 5 days in children and adolescents with refractory solid tumors. J Clin Oncol. 2009 Feb 1. 27(4):550-6. [Medline].

  40. Levy CF, Oo KZ, Fireman F, et al. Reversible posterior leukoencephalopathy syndrome in a child treated with bevacizumab. Pediatr Blood Cancer. 2009 May. 52(5):669-71. [Medline].

  41. Katzenstein HM, London WB, Douglass EC, et al. Treatment of unresectable and metastatic hepatoblastoma: a pediatric oncology group phase II study. J Clin Oncol. 2002 Aug 15. 20(16):3438-44. [Medline].

  42. Katzenstein HM, Rigsby C, Shaw PH, Mitchell TL, Haut PR, Kletzel M. Novel therapeutic approaches in the treatment of children with hepatoblastoma. J Pediatr Hematol Oncol. 2002 Dec. 24(9):751-5. [Medline].

  43. Fuchs J, Rydzynski J, Hecker H, et al. The influence of preoperative chemotherapy and surgical technique in the treatment of hepatoblastoma--a report from the German Cooperative Liver Tumour Studies HB 89 and HB 94. Eur J Pediatr Surg. 2002 Aug. 12(4):255-61. [Medline].

  44. Finegold MJ. Chemotherapy for suspected hepatoblastoma without efforts at surgical resection is a bad practice. Med Pediatr Oncol. 2002 Nov. 39(5):484-6. [Medline].

  45. van As JW, van den Berg H, van Dalen EC. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer. Cochrane Database Syst Rev. 2012 May 16. 5:CD009219. [Medline].

  46. Adesina AM, Lopez-Terrada D, Wong KK, et al. Gene expression profiling reveals signatures characterizing histologic subtypes of hepatoblastoma and global deregulation in cell growth and survival pathways. Hum Pathol. 2009 Jun. 40(6):843-53. [Medline].

  47. Aihara R, Ohno T, Mochiki E, et al. Gastrointestinal stromal tumor of the lesser omentum in a young adult patient with a history of hepatoblastoma: Report of a case. Surg Today. 2009. 39(4):349-52. [Medline].

  48. Beaunoyer M, Vanatta JM, Ogihara M, et al. Outcomes of transplantation in children with primary hepatic malignancy. Pediatr Transplant. 2007 Sep. 11(6):655-60. [Medline].

  49. Blaker H, Hofmann WJ, Rieker RJ, et al. Beta-catenin accumulation and mutation of the CTNNB1 gene in hepatoblastoma. Genes Chromosomes Cancer. 1999 Aug. 25(4):399-402. [Medline].

  50. Borger JA, Barbosa JL, Lehan CA. Chemotherapy combined with surgery in successful treatment of hepatoblastoma. J Fla Med Assoc. 1989 Dec. 76(12):1023-6. [Medline].

  51. Cairo S, Armengol C, De Reynies A, et al. Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer. Cancer Cell. 2008 Dec 9. 14(6):471-84. [Medline].

  52. Cohen MM Jr. Beckwith-Wiedemann syndrome: historical, clinicopathological, and etiopathogenetic perspectives. Pediatr Dev Pathol. 2005 May-Jun. 8(3):287-304. [Medline].

  53. Conran RM, Hitchcock CL, Waclawiw MA, Stocker JT, Ishak KG. Hepatoblastoma: the prognostic significance of histologic type. Pediatr Pathol. 1992 Mar-Apr. 12(2):167-83. [Medline].

  54. [Guideline] Czauderna P, Otte JB, Aronson DC, et al. Guidelines for surgical treatment of hepatoblastoma in the modern era--recommendations from the Childhood Liver Tumour Strategy Group of the International Society of Paediatric Oncology (SIOPEL). Eur J Cancer. 2005 May. 41(7):1031-6. [Medline].

  55. Czauderna P, Zbrzezniak G, Narozanski W, Korzon M, Wyszomirska M, Stoba C. Preliminary experience with arterial chemoembolization for hepatoblastoma and hepatocellular carcinoma in children. Pediatr Blood Cancer. 2006 Jun. 46(7):825-8. [Medline].

  56. D'Antiga L, Vallortigara F, Cillo U, et al. Features predicting unresectability in hepatoblastoma. Cancer. 2007 Sep 1. 110(5):1050-8. [Medline].

  57. Ehrlich PF, Greenberg ML, Filler RM. Improved long-term survival with preoperative chemotherapy for hepatoblastoma. J Pediatr Surg. 1997 Jul. 32(7):999-1002; discussion 1002-3. [Medline].

  58. Faraj W, Dar F, Marangoni G, et al. Liver transplantation for hepatoblastoma. Liver Transpl. 2008 Nov. 14(11):1614-9. [Medline].

  59. Feusner J, Buckley J, Robison L, et al. Prematurity and hepatoblastoma: more than just an association?. J Pediatr. 1998 Oct. 133(4):585-6. [Medline].

  60. Filler RM, Ehrlich PF, Greenberg ML, Babyn PS. Preoperative chemotherapy in hepatoblastoma. Surgery. 1991 Oct. 110(4):591-6; discussion 596-7. [Medline].

  61. Finegold MJ. Chemotherapy for suspected hepatoblastoma without efforts at surgical resection is a bad practice. Med Pediatr Oncol. 2002 Nov. 39(5):484-6. [Medline].

  62. Gutweiler JR, Yu DC, Kim HB, et al. Hepatoblastoma presenting with focal nodular hyperplasia after treatment of neuroblastoma. J Pediatr Surg. 2008 Dec. 43(12):2297-300. [Medline].

  63. Herzog CE, Andrassy RJ, Eftekhari F. Childhood cancers: hepatoblastoma. Oncologist. 2000. 5(6):445-53. [Medline].

  64. Horton JD, Lee S, Brown SR, Bader J, Meier DE. Survival trends in children with hepatoblastoma. Pediatr Surg Int. 2009 May. 25(5):407-12. [Medline].

  65. Kasahara M, Ueda M, Haga H, et al. Living-donor liver transplantation for hepatoblastoma. Am J Transplant. 2005 Sep. 5(9):2229-35. [Medline].

  66. King SJ, Babyn PS, Greenberg ML, Phillips MJ, Filler RM. Value of CT in determining the resectability of hepatoblastoma before and after chemotherapy. AJR Am J Roentgenol. 1993 Apr. 160(4):793-8. [Medline].

  67. Li FP, Thurber WA, Seddon J, Holmes GE. Hepatoblastoma in families with polyposis coli. JAMA. 1987 May 8. 257(18):2475-7. [Medline].

  68. Lopez-Terrada D. Integrating the diagnosis of childhood malignancies. Adv Exp Med Biol. 2006. 587:121-37. [Medline].

  69. Mejia A, Langnas AN, Shaw BW, Torres C, Sudan DL. Living and deceased donor liver transplantation for unresectable hepatoblastoma at a single center. Clin Transplant. 2005 Dec. 19(6):721-5. [Medline].

  70. Meyers RL, Katzenstein HM, Malogolowkin MH. Predictive value of staging systems in hepatoblastoma. J Clin Oncol. 2007 Feb 20. 25(6):737. [Medline].

  71. Mody RJ, Pohlen JA, Malde S, Strouse PJ, Shulkin BL. FDG PET for the study of primary hepatic malignancies in children. Pediatr Blood Cancer. 2006 Jul. 47(1):51-5. [Medline].

  72. Molmenti EP, Wilkinson K, Molmenti H, et al. Treatment of unresectable hepatoblastoma with liver transplantation in the pediatric population. Am J Transplant. 2002 Jul. 2(6):535-8. [Medline].

  73. Mulcahy N. Dramatic Survival Gain in Kids With High-Risk Hepatoblastoma. Medscape Medical News. Aug 15 2013. Available at Accessed: August 20, 2013.

  74. Otte JB, de Ville de Goyet J. The contribution of transplantation to the treatment of liver tumors in children. Semin Pediatr Surg. 2005 Nov. 14(4):233-8. [Medline].

  75. Otte JB, de Ville de Goyet J, Reding R. Liver transplantation for hepatoblastoma: indications and contraindications in the modern era. Pediatr Transplant. 2005 Oct. 9(5):557-65. [Medline].

  76. Pollock BH, Jenson HB, Leach CT, et al. Risk factors for pediatric human immunodeficiency virus-related malignancy. JAMA. 2003 May 14. 289(18):2393-9. [Medline].

  77. Pritchard J, Brown J, Shafford E, et al. Cisplatin, doxorubicin, and delayed surgery for childhood hepatoblastoma: a successful approach--results of the first prospective study of the International Society of Pediatric Oncology. J Clin Oncol. 2000 Nov 15. 18(22):3819-28. [Medline].

  78. Quinn JJ, Altman AJ, Robinson HT, Cooke RW, Hight DW, Foster JH. Adriamycin and cisplatin for hepatoblastoma. Cancer. 1985 Oct 15. 56(8):1926-9. [Medline].

  79. Raney B. Hepatoblastoma in children: a review. J Pediatr Hematol Oncol. 1997 Sep-Oct. 19(5):418-22. [Medline].

  80. Ranganathan S, Tan X, Monga SP. beta-Catenin and met deregulation in childhood Hepatoblastomas. Pediatr Dev Pathol. 2005 Jul-Aug. 8(4):435-47. [Medline].

  81. Reynolds M, Douglass EC, Finegold M, Cantor A, Glicksman A. Chemotherapy can convert unresectable hepatoblastoma. J Pediatr Surg. 1992 Aug. 27(8):1080-3; discussion 1083-4. [Medline].

  82. Richter A, Grabhorn E, Schulz A, Schaefer HJ, Burdelski M, Ganschow R. Hepatoblastoma in a child with progressive familial intrahepatic cholestasis. Pediatr Transplant. 2005 Dec. 9(6):805-8. [Medline].

  83. Ross JA, Gurney JG. Hepatoblastoma incidence in the United States from 1973 to 1992. Med Pediatr Oncol. 1998 Mar. 30(3):141-2. [Medline].

  84. Sallam A, Paes B, Bourgeois J. Neonatal hepatoblastoma: two cases posing a diagnostic dilemma, with a review of the literature. Am J Perinatol. 2005 Nov. 22(8):413-9. [Medline].

  85. Srinivasan P, McCall J, Pritchard J, et al. Orthotopic liver transplantation for unresectable hepatoblastoma. Transplantation. 2002 Sep 15. 74(5):652-5. [Medline].

  86. [Guideline] Tan TY, Amor DJ. Tumour surveillance in Beckwith-Wiedemann syndrome and hemihyperplasia: a critical review of the evidence and suggested guidelines for local practice. J Paediatr Child Health. 2006 Sep. 42(9):486-90. [Medline].

  87. Tomizawa M, Saisho H. Signaling pathway of insulin-like growth factor-II as a target of molecular therapy for hepatoblastoma. World J Gastroenterol. 2006 Oct 28. 12(40):6531-5. [Medline].

  88. Tomlinson GE, Douglass EC, Pollock BH, Finegold MJ, Schneider NR. Cytogenetic evaluation of a large series of hepatoblastomas: numerical abnormalities with recurring aberrations involving 1q12-q21. Genes Chromosomes Cancer. 2005 Oct. 44(2):177-84. [Medline].

  89. Trobaugh-Lotrario AD, Tomlinson GE, Finegold MJ, Gore L, Feusner JH. Small cell undifferentiated variant of hepatoblastoma: adverse clinical and molecular features similar to rhabdoid tumors. Pediatr Blood Cancer. 2009 Mar. 52(3):328-34. [Medline].

  90. Tsuchida Y, Ikeda H, Suzuki N, et al. A case of well-differentiated, fetal-type hepatoblastoma with very low serum alpha-fetoprotein. J Pediatr Surg. 1999 Dec. 34(12):1762-4. [Medline].

  91. Vogl TJ, Scheller A, Jakob U, Zangos S, Ahmed M, Nabil M. Transarterial chemoembolization in the treatment of hepatoblastoma in children. Eur Radiol. 2006 Jun. 16(6):1393-6. [Medline].

  92. Wang JD, Chang TK, Chen HC, et al. Pediatric liver tumors: initial presentation, image finding and outcome. Pediatr Int. 2007 Aug. 49(4):491-6. [Medline].

  93. Warmann SW, Frank H, Heitmann H, et al. Bcl-2 Gene Silencing in Pediatric Epithelial Liver Tumors. J Surg Res. 2008 Jan. 144(1):43-48. [Medline].

  94. Warmann SW, Heitmann H, Teichmann B, et al. Effects of P-glycoprotein modulation on the chemotherapy of xenotransplanted human hepatoblastoma. Pediatr Hematol Oncol. 2005 Jul-Aug. 22(5):373-86. [Medline].

  95. Zimmermann A. The emerging family of hepatoblastoma tumours: from ontogenesis to oncogenesis. Eur J Cancer. 2005 Jul. 41(11):1503-14. [Medline].

  96. Zsiros J, Brugieres L, Brock P, Roebuck D, Maibach R, Zimmermann A, et al. Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study. Lancet Oncol. 2013 Aug. 14(9):834-42. [Medline]. [Full Text].

Clear cell hepatoblastoma. Hematoxylin and eosin stain. Image courtesy of Denise Malicki, MD.
Embryonal hepatoblastoma. Hematoxylin and eosin stain. Image courtesy of Denise Malicki, MD.
Fetal components of hepatoblastoma. Hematoxylin and eosin stain. Image courtesy of Denise Malicki, MD.
Hepatoblastoma. Normal liver tissue. Hematoxylin and eosin stain. Image courtesy of Denise Malicki, MD.
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.